This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Wednesday, September 11, 2013
VA Hospital Mistakes: Leaders got bonuses despite problems within their systems
Reporting by
PITTSBURGH, Pa. -- Department of Veterans Affairs officials had trouble explaining to a House committee why department officials received awards and bonuses while hospitals they oversaw were the sites of infectious disease outbreaks and suicide deaths in recent years.
Buffalo was among the cities where leaders got bonuses despite problems within their systems. The Upstate New York network director, David West, got nearly $26,000 in bonuses despite revelations that workers re-used disposable insulin pens on patients at the Buffalo hospital, putting veterans at risk of HIV or hepatitis infections.
Continue reading....
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment